Connect with us
Information

Australia
North America
World

Investing News NetworkYour trusted source for investing success

North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides

Precious Metals
Battery Metals
Base Metals
Energy
Critical Metals

Pharmaceutical Market

Pharmaceutical News

Pharmaceutical Stocks

Pharmaceutical Market
Pharmaceutical News
Pharmaceutical Stocks

AbbVie Inc.

NYSE:ABBV:US

Featured Articles and Interviews

Feb 11, 2025

What is In-Licensing?

Jan 22, 2025

Biotech Market Forecast: Top Trends for Biotech in 2025

Jan 16, 2025

What are Dividend Stocks?

More Featured Articles and Inverviews

Press Releases

Apr 10, 2025

New York Plastic Surgical Group and Deep Blue Med Spa Receive State and National Recognition by Allergan Aesthetics

Apr 07, 2025

AbbVie Announces European Commission Approval of RINVOQ® for the Treatment of Adults with Giant Cell Arteritis

Mar 31, 2025

AbbVie to Host First-Quarter 2025 Earnings Conference Call

More Press Releases

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Go Deeper

AI Powered

Microscopic view of stem cells.

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks of 2025

Interactive Chart

Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.